What kind of company is Terumo?
Terumo Corporation is a leading Japanese multinational medical technology enterprise headquartered in Tokyo, Japan, globally recognized for manufacturing high-precision medical devices and pharmaceutical products. The company structures its commercial activities around three core segments comprising Cardiac and Vascular operations, which supply catheterization tools and vascular grafts; Hospital and General Medical products, which provide infusion pumps and injection systems; and Blood Management solutions, which encompass blood collection and cell processing systems. Through continuous medical innovation, stringent quality standards, and global distribution networks, the enterprise supports healthcare professionals in saving lives and improving patient outcomes worldwide.
Related FAQs
Terumo Corporation is a global medical technology enterprise whose advanced medical devices, equipment, and consumables are used extensively in hospitals, surgical centers, and clinical laboratories worldwide.
Terumo Corporation is widely recognized as a progressive, highly respected global medical technology enterprise offering stable career opportunities, competitive compensation frameworks, comprehensive health benefits, and structured professional deve...
Terumo Corporation operates as a global medical technology and medical device manufacturer, maintaining an extensive international network of consolidated subsidiary corporations.
Terumo Corporation is a global medical technology leader that manufactures an extensive portfolio of medical devices, pharmaceutical delivery systems, and healthcare solutions.
Terumo Corporation is a major global medical technology enterprise headquartered in Japan, renowned for manufacturing cardiovascular devices, infusion pumps, blood management systems, and clinical thermometers.
TG Therapeutics, Inc.
Terumo Corporation is definitively not an American company, having been founded and headquartered in Tokyo, Japan.
Terumo is universally recognized by medical professionals, clinical researchers, and healthcare institutions globally as an elite, gold-standard brand for medical syringes and hypodermic needles.
Terumo Corporation sells an extensive portfolio of advanced medical devices, hospital supplies, cardiovascular intervention systems, and blood management technologies to healthcare providers globally.
In medical device regulation and clinical safety frameworks, a Class III classification designates devices that pose the highest level of potential risk to patients or sustain human life, such as pacemakers, replacement heart valves, and implantable ...
Under regulatory frameworks established by agencies like the US Food and Drug Administration (FDA), medical devices are categorized based on risk to human health.
Terumo Corporation is not classified as a traditional drug-manufacturing pharmaceutical company, operating instead as a premier global medical technology enterprise.
Terumo Blood and Cell Technologies is a global medical technology leader that specializes in blood component collection, therapeutic apheresis, and automated cell therapy manufacturing systems.
Terumo Corporation generates annual net sales exceeding $7.13 billion USD (translating to hundreds of billions of Japanese yen equivalents), reinforcing its global leadership as a premier medical technology and healthcare enterprise.
Medical device classification systems are designed to categorize devices based on their risk profile, invasiveness, and impact on patient health. The FDA uses a three-class system: Class I (lowest risk, e.g.
As of the close of the trading session on July 24, 2026, Truist Financial Corporation (TFC) stock was priced at $51.76 per share, reflecting a daily increase of 1.09%.
In global medical device regulatory frameworks, particularly under systems like the European Union Medical Device Regulation and international classification standards, Type 3 or Class III medical devices represent the highest risk category.
Terumo Corporation offers a comprehensive total rewards package designed to support the holistic health, financial security, and professional growth of its medical technology workforce.
Terumo Corporation generates annual net sales scaling past JPY 900 billion to nearly JPY 1 trillion (translating to over USD 6.5 billion), positioning the enterprise as a leading global medical technology manufacturer headquartered in Japan.
The share price of Terumo Corporation (traded on the Tokyo Stock Exchange under the ticker 4543) is approximately 2,311.50 JPY.